Literature DB >> 26686230

Toward the treatment for Alzheimer's disease: adsorption is primary mechanism of removing amyloid β protein with hollow-fiber dialyzers of the suitable materials, polysulfone and polymethyl methacrylate.

Kazunori Kawaguchi1, Akira Saigusa2, Shinji Yamada3, Takehiro Gotoh4, Shigeru Nakai5, Yoshiyuki Hiki5, Midori Hasegawa6, Yukio Yuzawa6, Nobuya Kitaguchi7.   

Abstract

The accumulation of amyloid β protein (Aβ) in the brain reflects cognitive impairment in Alzheimer's disease. We hypothesized that the rapid removal of Aβ from the blood by an extracorporeal system may act as a peripheral Aβ sink from the brain. The present study aimed to determine the optimal materials and modality for Aβ removal by hemodialyzers. In a batch analysis, hollow-fiber fragments of polysulfone (PSf) and polymethyl methacrylate (PMMA) showed greater removal efficiency of Aβ than did other materials, such as cellulose-triacetates and ethylene-vinyl alcohol copolymer (PSf:PMMA at 30 min, 98.6 ± 2.4 %:97.8 ± 0.4 % for Aβ1-40 and 96.6 ± 0.3 %:99.0 ± 1.0 % for Aβ1-42). In a modality study, the Aβ solution was applied to PSf dialyzers and circulated in the dialysis and Air-filled adsorption-mode (i.e., the outer space of the hollow fibers was filled with air) or phosphate-buffered saline (PBS)-filled adsorption modes. The Aβ1-40 removal efficiency of the pre/post dialyzer in the Air-filled adsorption-mode was the highest (62.4 ± 12.6 %, p = 0.007). In a flow rate study in the Air-filled adsorption-mode, 200 mL/min showed the highest Aβ1-40 reduction rate of pool solution (97.3 ± 0.8 % at 15 min) compared with 20 mL/min (p = 0.00001) and 50 mL/min (p = 0.00382). PMMA dialyzers showed similar high reduction rates. Thus, the optimal modality for Aβ removal was the adsorption-mode with PSf or PMMA hollow fibers at around 50 mL/min flow rate, which seems to be suitable for clinical use.

Entities:  

Keywords:  Alzheimer’s disease; Amyloid-β (Aβ); Apheresis; Hemodialysis

Mesh:

Substances:

Year:  2015        PMID: 26686230     DOI: 10.1007/s10047-015-0878-1

Source DB:  PubMed          Journal:  J Artif Organs        ISSN: 1434-7229            Impact factor:   1.731


  13 in total

Review 1.  Alzheimer's disease: genes, proteins, and therapy.

Authors:  D J Selkoe
Journal:  Physiol Rev       Date:  2001-04       Impact factor: 37.312

2.  Potential therapeutic system for Alzheimer's disease: removal of blood Aβs by hemodialzyers and its effect on the cognitive functions of renal-failure patients.

Authors:  Masao Kato; Kazunori Kawaguchi; Sigeru Nakai; Kazutaka Murakami; Hideo Hori; Atsushi Ohashi; Yoshiyuki Hiki; Shinji Ito; Yasunobu Shimano; Nobuo Suzuki; Satoshi Sugiyama; Hiroshi Ogawa; Hiroko Kusimoto; Tatsuro Mutoh; Yukio Yuzawa; Nobuya Kitaguchi
Journal:  J Neural Transm (Vienna)       Date:  2012-06-15       Impact factor: 3.575

3.  Novel therapeutic approach for Alzheimer's disease by removing amyloid beta protein from the brain with an extracorporeal removal system.

Authors:  Kazunori Kawaguchi; Nobuya Kitaguchi; Shigeru Nakai; Kazutaka Murakami; Kunihiko Asakura; Tatsuro Mutoh; Yoshiro Fujita; Satoshi Sugiyama
Journal:  J Artif Organs       Date:  2010-02-23       Impact factor: 1.731

4.  Reduction of Alzheimer's disease amyloid-β in plasma by hemodialysis and its relation to cognitive functions.

Authors:  N Kitaguchi; K Kawaguchi; S Nakai; K Murakami; S Ito; H Hoshino; H Hori; A Ohashi; Y Shimano; N Suzuki; Y Yuzawa; T Mutoh; S Sugiyama
Journal:  Blood Purif       Date:  2011-02-24       Impact factor: 2.614

5.  Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system.

Authors:  Robert D Bell; Abhay P Sagare; Alan E Friedman; Gurrinder S Bedi; David M Holtzman; Rashid Deane; Berislav V Zlokovic
Journal:  J Cereb Blood Flow Metab       Date:  2006-11-01       Impact factor: 6.200

6.  A potential therapeutic system for Alzheimer's disease using adsorbents with alkyl ligands for removal of blood amyloid β.

Authors:  Kazunori Kawaguchi; Masato Takeuchi; Hiromasa Yamagawa; Kazutaka Murakami; Sigeru Nakai; Hideo Hori; Atsushi Ohashi; Yoshiyuki Hiki; Nobuo Suzuki; Satoshi Sugiyama; Yukio Yuzawa; Nobuya Kitaguchi
Journal:  J Artif Organs       Date:  2012-12-02       Impact factor: 1.731

7.  A prospective study on blood Aβ levels and the cognitive function of patients with hemodialysis: a potential therapeutic strategy for Alzheimer's disease.

Authors:  Nobuya Kitaguchi; Midori Hasegawa; Shinji Ito; Kazunori Kawaguchi; Yoshiyuki Hiki; Sigeru Nakai; Nobuo Suzuki; Yasunobu Shimano; Osamu Ishida; Hiroko Kushimoto; Masao Kato; Sigehisa Koide; Kyoko Kanayama; Takashi Kato; Kengo Ito; Hiroshi Takahashi; Tatsuro Mutoh; Satoshi Sugiyama; Yukio Yuzawa
Journal:  J Neural Transm (Vienna)       Date:  2015-07-31       Impact factor: 3.575

8.  Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study.

Authors:  O L Lopez; L H Kuller; P D Mehta; J T Becker; H M Gach; R A Sweet; Y F Chang; R Tracy; S T DeKosky
Journal:  Neurology       Date:  2008-04-09       Impact factor: 9.910

9.  Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.

Authors:  Christoph Hock; Uwe Konietzko; Johannes R Streffer; Jay Tracy; Andri Signorell; Britta Müller-Tillmanns; Ulrike Lemke; Katharina Henke; Eva Moritz; Esmeralda Garcia; M Axel Wollmer; Daniel Umbricht; Dominique J F de Quervain; Marc Hofmann; Alessia Maddalena; Andreas Papassotiropoulos; Roger M Nitsch
Journal:  Neuron       Date:  2003-05-22       Impact factor: 17.173

10.  Amyloid-beta peptide (Abeta) neurotoxicity is modulated by the rate of peptide aggregation: Abeta dimers and trimers correlate with neurotoxicity.

Authors:  Lin Wai Hung; Giuseppe D Ciccotosto; Eleni Giannakis; Deborah J Tew; Keyla Perez; Colin L Masters; Roberto Cappai; John D Wade; Kevin J Barnham
Journal:  J Neurosci       Date:  2008-11-12       Impact factor: 6.167

View more
  5 in total

1.  Adsorptive filtration systems for effective removal of blood amyloid β: a potential therapy for Alzheimer's disease.

Authors:  Nobuya Kitaguchi; Kazunori Kawaguchi; Kazunori Yamazaki; Hiroshi Kawachi; Miwa Sakata; Megumi Kaneko; Masao Kato; Kazuyoshi Sakai; Norimi Ohashi; Midori Hasegawa; Yoshiyuki Hiki; Yukio Yuzawa
Journal:  J Artif Organs       Date:  2017-12-11       Impact factor: 1.731

2.  Aβ Influx into the Blood Evoked by Different Blood Aβ Removal Systems: A Potential Therapy for Alzheimer's Disease.

Authors:  Nobuya Kitaguchi; Kazunori Kawaguchi; Miwa Sakata; Hiroki Aoki; Kazunori Yamazaki; Megumi Kaneko; Jun Kinomura; Masao Kato; Midori Hasegawa; Nobuo Suzuki; Masao Mizuno; Yukio Yuzawa
Journal:  Neuropsychiatr Dis Treat       Date:  2021-07-13       Impact factor: 2.570

3.  Removal of blood amyloid-β with hemodialysis reduced brain amyloid-β, confirmed by brain imaging: a case report.

Authors:  Nobuya Kitaguchi; Takashi Kato; Shinji Matsunaga; Kyoko Hirano; Kaori Iwata; Kazunori Kawaguchi; Kiyoshi Fujita; Hajime Takechi; Midori Hasegawa; Yukio Yuzawa; Kengo Ito
Journal:  Neuropsychiatr Dis Treat       Date:  2018-11-01       Impact factor: 2.570

4.  'Amytrapper', a Novel Immobilized Sepharose API Matrix, Removes Amyloid-β from Circulation in vitro.

Authors:  Omkar Gandbhir; Pazhani Sundaram
Journal:  J Alzheimers Dis Rep       Date:  2019-02-04

5.  Removal of Aβ Oligomers from the Blood: A Potential Therapeutic System for Alzheimer's Disease.

Authors:  Yuta Saito; Miwa Sakata; Moe Kobayakawa; Hiroshi Kawachi; Kazunori Kawaguchi; Yoshiyuki Hiki; Masao Kato; Mayuko Mori; Midori Hasegawa; Norimi Ohashi; Yukio Yuzawa; Nobuya Kitaguchi
Journal:  Neuropsychiatr Dis Treat       Date:  2020-03-03       Impact factor: 2.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.